Julie Forman-Kay is program head in molecular medicine at the Hospital for Sick Children in Toronto, Canada. She received her B.Sc. in chemistry from the Massachusetts Institute of Technology and her Ph.D. in molecular biophysics andd biochemistry from Yale University. The major focus of her lab is to provide biological insights into how dynamic properties of proteins are related to function and methodological tools to enable better understanding of dynamic and disordered states. Most recently, her lab has probed the biophysics of protein phase separation and how it regulates cellular condensates and biological function.
Julie Forman-Kay
Program head
Hospital for Sick Children
From this contributor
How microscopic ‘condensates’ in cells might contribute to autism
A controversial idea about how cells compartmentalize their contents into droplets — like beads of oil in water — could be key to understanding autism, says Julie Forman-Kay.
How microscopic ‘condensates’ in cells might contribute to autism
By
Angie Voyles Askham
23 February 2021 | 7 min read
Explore more from The Transmitter
Watching the mind build a world: Lucid dreaming as a model for generative perception
Lucid dreaming offers a rare opportunity to observe and probe perception from within.
Watching the mind build a world: Lucid dreaming as a model for generative perception
Lucid dreaming offers a rare opportunity to observe and probe perception from within.
By
Magdalena Paluchowska
13 July 2026 | 8 min read
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
By
Natalia Mesa
9 July 2026 | 5 min read
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
By
Kenneth Harris
9 July 2026 | 9 min read